Patents by Inventor Hosung Min

Hosung Min has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPECIFIC BINDING AGENTS OF HUMAN ANGIOPOEITIN-2
    Publication number: 20100286060
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: March 23, 2010
    Publication date: November 11, 2010
    Applicant: Amgen Inc.
    Inventors: Jonathan Daniel OLINER, Hosung Min
  • Polynucleotides encoding myostatin binding agents
    Patent number: 7803923
    Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: September 28, 2010
    Assignee: Amgen Inc.
    Inventors: Hq Han, Hosung Min, Thomas C. Boone
  • PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1
    Publication number: 20100240590
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5DC7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Application
    Filed: May 26, 2010
    Publication date: September 23, 2010
    Inventors: Hosung MIN, Hailing Hsu, Fei Xiong
  • Peptides and related molecules that modulate nerve growth factor activity
    Publication number: 20100240582
    Abstract: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.
    Type: Application
    Filed: January 24, 2008
    Publication date: September 23, 2010
    Inventors: Thomas C. Boone, Kenneth D. Wild, Karen C. Sitney, Hosung Min, Bruce Kimmel
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Patent number: 7790674
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: September 7, 2010
    Assignee: Amgen Inc.
    Inventors: Jonathan Daniel Oliner, Hosung Min
  • Peptides and related molecules that bind to TALL-1
    Patent number: 7737111
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO:100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO:104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO:105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO:106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO:107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO:109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: June 15, 2010
    Assignee: Amgen, Inc.
    Inventors: Hosung Min, Hailing Hsu, Fei Xiong
  • Specific binding agents of human angiopoietin-2
    Patent number: 7723499
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: May 25, 2010
    Assignee: Amgen Inc.
    Inventors: Jonathan Daniel Oliner, Hosung Min
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Patent number: 7666831
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: February 23, 2010
    Assignee: Amgen Inc.
    Inventors: Jonathan Daniel Oliner, Hosung Min
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Patent number: 7666839
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: February 23, 2010
    Assignee: Amgen Inc.
    Inventors: Jonathan Daniel Oliner, Hosung Min
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Patent number: 7666832
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: February 23, 2010
    Assignee: Amgen Inc.
    Inventors: Jonathan Daniel Oliner, Hosung Min
  • Myostatin binding agents
    Publication number: 20090227517
    Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.
    Type: Application
    Filed: January 30, 2009
    Publication date: September 10, 2009
    Applicant: Amgen Inc.
    Inventors: Hq Han, Hosung Min, Thomas Charles Boone
  • Binding agents which inhibit myostatin
    Publication number: 20090220491
    Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.
    Type: Application
    Filed: February 10, 2009
    Publication date: September 3, 2009
    Applicant: Amgen Inc.
    Inventors: Hq Han, Hosung Min, Thomas Charles Boone
  • Myostatin binding agents
    Patent number: 7511012
    Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: March 31, 2009
    Assignee: Amgen Inc.
    Inventors: Hq Han, Hosung Min, Thomas Charles Boone
  • Specific Binding Agents of Human Angiopoietin-2
    Publication number: 20090054323
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: December 7, 2007
    Publication date: February 26, 2009
    Applicant: AMGEN INC.
    Inventors: Jonathan Daniel Oliner, Hosung Min
  • Peptides and related compounds having thrombopoietic activity
    Publication number: 20090011497
    Abstract: The present invention relates generally to novel peptides and related compounds that have thrombopoietic activity. The compounds of the invention may be used to increase production of platelets or platelet precursors (e.g. megakaryocytes) in a mammal.
    Type: Application
    Filed: February 19, 2008
    Publication date: January 8, 2009
    Inventors: Hosung Min, Karen C. Sitney, Cynthia Hartley
  • Peptides and related molecules that modulate nerve growth factor activity
    Patent number: 7371559
    Abstract: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: May 13, 2008
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Kenneth C. Wild, Karen C. Sitney, Hosung Min, Bruce Kimmel
  • Thrombopoietic compounds
    Publication number: 20080070840
    Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.
    Type: Application
    Filed: June 18, 2007
    Publication date: March 20, 2008
    Inventors: Hosung Min, Kenneth Walker, Colin Gegg, Francesco Galimi, Jeonghoon Sun, Mei-Mei Tsai
  • Peptides and related compounds having thrombopoietic activity
    Patent number: 7332474
    Abstract: The present invention relates generally to novel peptides and related compounds that have thrombopoietic activity. The compounds of the invention may be used to increase production of platelets or platelet precursors (e.g. megakaryocytes) in a mammal.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: February 19, 2008
    Assignee: Amgen Inc.
    Inventors: Hosung Min, Karen C. Sitney, Cynthia Hartley
  • Methods of treatment using specific binding agents of human angiopoietin-2
    Publication number: 20070225221
    Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
    Type: Application
    Filed: August 4, 2006
    Publication date: September 27, 2007
    Applicant: AMGEN INC.
    Inventors: Jonathan Oliner, Hosung Min
  • Peptides and related molecules that bind to TALL-1
    Patent number: 7259137
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: August 21, 2007
    Assignee: Amgen Inc.
    Inventors: Hosung Min, Hailing Hsu, Fei Xiong